The landscape of medical oncology in Europe by 2020
de Azambuja, E., Ameye, L., Paesmans, M., Zielinski, C.C., Piccart-Gebhart, M., Preusser, M.
Published in Annals of oncology (01.02.2014)
Published in Annals of oncology (01.02.2014)
Get full text
Journal Article
Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent
Carteni, G, Manegold, C, Garcia, G. Martin, Siena, S, Zielinski, C.C, Amadori, D, Liu, Y, Blatter, J, Visseren-Grul, C, Stahel, R
Published in Lung cancer (Amsterdam, Netherlands) (01.05.2009)
Published in Lung cancer (Amsterdam, Netherlands) (01.05.2009)
Get full text
Journal Article
2928 Laboratory parameters have independent prognostic impact in patients with newly diagnosed brain metastases: analysis of 1201 cases
Berghoff, A.S, Koller, R, Widhalm, G, Dieckmann, K, Zielinski, C.C, Birner, P, Bartsch, R, Preusser, M
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
2927 Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in diffuse and anaplastic gliomas
Berghoff, A.S, Kiesel, B, Widhalm, G, Rajky, O, Ricken, G, Wöhrer, A, Dieckmann, K, Zielinski, C.C, Marosi, C, Preusser, M
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases
Bergen, E, Berghoff, A.S, Rudas, M, Dubsky, P, Gnant, M, Dieckmann, K, Widhalm, G, Zielinski, C.C, Steger, G.G, Preusser, M, Bartsch, R
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Zielinski, C.C, Lang, I, Inbar, M, Kahan, Z, Greil, R, Beslija, S, Stemmer, S.M, Zvirbule, Z, Steger, G.G, Melichar, B, Pienkowski, T, Sirbu, D, Petruzelka, L, Eniu, A, Nisenbaum, B, Dank, M, Anghel, R, Messinger, D, Brodowicz, T
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial
Prager, G, Unseld, M, Waneck, F, Raderer, M, Krainer, M, Fuereder, T, Hejna, M, Staber, P, Scheithauer, W, Schmidinger, M, Thallinger, C, Farkas, L, Reinthaller, A, Polterauer, S, Wrba, F, Muellauer, L, Mader, R, Zielinski, C.C
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer
Bartsch, R, Bago-Horvath, Z, Pluschnig, U, Berghoff, A, Dubsky, P, Mader, R.M, Fitzal, F, Gnant, M, Zielinski, C.C, Steger, G.G
Published in European journal of cancer (1990) (01.03.2012)
Published in European journal of cancer (1990) (01.03.2012)
Get full text
Journal Article
5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data
Inbar, M, Lang, I, Kahán, Z, Greil, R, Beslija, S, Stemmer, S.M, Kaufman, B, Zvirbule, Z, Steger, G.G, Zielinski, C.C
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
7106 POSTER DISCUSSION The Proteasome-inhibitor Bortezomib is Active in Human Urothelial Cancer Cell Lines in Combination With the Tyrosine-kinase Inhibitor Sunitinib or Cisplatinum
Voql, U.M, Berger, W, Bojic, M, Lamm, W, Haitel, A, Kramer, G, Zielinski, C.C, Schmidinger, M
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
5061 POSTER Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer
Bartsch, R, Berghoff, A, Pluschnig, U, Bago-Horvath, Z, Dubsky, P, Rottenfusser, A, Gnant, M, Mader, R, Zielinski, C.C, Steger, G.G
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
Clinical trial design issues: Session 1
Milsted, R, Hinz, T, Zielinski, C.C
Published in European journal of cancer supplements (01.12.2007)
Published in European journal of cancer supplements (01.12.2007)
Get full text
Journal Article
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Subbiah, V., Kreitman, R.J., Wainberg, Z.A., Cho, J.Y., Schellens, J.H.M., Soria, J.C., Wen, P.Y., Zielinski, C.C., Cabanillas, M.E., Boran, A., Ilankumaran, P., Burgess, P., Romero Salas, T., Keam, B.
Published in Annals of oncology (01.04.2022)
Published in Annals of oncology (01.04.2022)
Get full text
Journal Article
22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases
Tobias, J., Drinić, M., Högler, S., Schmid, A., Garner-Spitzer, E., Kenner, L., Kundi, M., Zielinski, C.C., Wiedermann, U.
Published in Annals of oncology (01.03.2022)
Published in Annals of oncology (01.03.2022)
Get full text
Journal Article
114 The dual PI3K/mTOR blocker NVP-BEZ235 sensitizes cancer cells against irreversible ErbB inhibitors
Grunt, T.W, Brünner-Kubath, C, Shabbir, W, Saferding, V, Wagner, R, Singer, C.F, Valent, P, Berger, W, Zielinski, C.C, Grusch, M
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
5088 Analysis of factors predicting response to second-line trastuzumab- based therapy in patients (pts) with Her2-positive advanced breast cancer (ABC)
Bartsch, R, DeVries, C, Pluschnig, U, Dubsky, P, Horvath, S, Rudas, M, Mader, R.M, Gnant, M, Zielinski, C.C, Steger, G.G
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
Lang, I, Inbar, M, Steger, G, Greil, R, Zvirbule, Z, Beslija, S, Kahán, Z, Taskova, V, Kaufmann, B, Zielinski, C.C
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
Combination of trastuzumab and gemcitabine as salvage therapy in heavily pretreated patients with metastatic breast cancer
Bartsch, R, Wenzel, C, Pluschnig, U, Altorjai, G, Dubsky, P, Scheurer, R, Rottenfusser, A, Gnant, M, Zielinski, C.C, Steger, G.G
Published in European journal of cancer supplements (2008)
Published in European journal of cancer supplements (2008)
Get full text
Journal Article